We will pursue the following aims in myelofibrosis:

Aim 1. Early detection of BM fibrosis in MPN (P5, P6)

Aim 2. Prevention of progression to overt myelofibrosis (P1, P2, P4, P5, P6)

Aim 3. Treatment of overt myelofibrosis (P1, P2, P3, P4)

P1: Spatial transcriptome mapping to identify druggable targets in the step-wise progression of bone marrow fibrosis

P2: Molecular targeting of STAT3-activating cytokines in the MPN pre-fibrotic niche

P3: Dissecting the spatio-temporal dynamics of bone marrow fibrosis in MPN in response to therapy

P4: Targeting the bone marrow inflammatory niche in myelofibrosis with nanomedicine therapeutics

P5: Targeting aberrant DNA methylation in myeloproliferative neoplasms

P6: Impact of Disease Burden and Timing of Disease Initiation on the Response to Interferon-alpha (IFNa) in MPN-associated myelofibrosis

SP: Integrative platform for clinical and genomic data in Myeloproliferative Neoplasms (MPN)